Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed against Northwest Biotherapeutics, Inc. (“Northwest Biotherapeutics”) (NasdaqCM: NWBO) and several officers and directors for acts taken during the period of March 8, 2013 and August 20, 2015 (the “Class Period”).

Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of Northwest Biotherapeutics, Inc. If you are an affected Northwest Biotherapeutics, Inc. shareholder and want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC via email at shareholders@thebriscoelawfirm.com, Patrick Powers at Powers Taylor LLP via email at shareholder@powerstaylor.com, or call toll free at (877) 728-9607. There is no cost or fee to you.

According to the complaint, the defendants are alleged to have violated certain provisions of the Securities Exchange Act of 1934. Specifically, the complaint alleges, among other things, that defendants issued statements suggesting that the Company failed to disclose the positive results from its DCVax-Direct Trial, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer, were based on preliminary trial results which had not been reviewed or analyzed by the hospitals conducting the trial. The complaint also alleges that Northwest Biotherapeutics utilized an aggressive stock promotion campaign in 2014. Also, the complaint alleges that German medical authorities required additional information from the Company in order for the DCVax-L Trial to continue uninterrupted.

On June 19, 2014, TheStreet.com reported that MD Anderson Cancer Center, the facility in charge of the clinical trial with direct funding from Northwest Biotherapeutics, publicly rebuked the Company’s unjustified and promotional allegations about the clinical results of DCVax-Direct. On July 7, 2014, an article published in Seekingalpha.com accused Northwest Biotherapeutics of hiring authors who have used fictitious identities and fake credentials within healthcare or finance as part of a stock promotion scheme. Then, on August 21, 2015, Northwest Biotherapeutics Phase 3 DCVax-L brain cancer treatment clinical trial was announced to be temporarily halted by German medical regulators. After each of these announcements, NWBO stock dropped significantly.

The Briscoe Law Firm, PLLC is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.

The Briscoe Law Firm, PLLCWillie Briscoe, 877-728-9607shareholders@thebriscoelawfirm.comorPowers Taylor LLPPatrick Powers, 877-728-9607shareholder@powerstaylor.com

Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Northwest Biotherapeutics (QB) Charts.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Northwest Biotherapeutics (QB) Charts.